Pivotal Trials in the Realm of Ovarian Cancer
Efficacy | ZEJULA (niraparib) for HCPs
Zejula (niraparib) com resultados positivos como terapêutica de primeira linha | Netfarma
Use of First-Line PARP Inhibitors in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | Oncology and Therapy
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Efficacy of Niraparib by Timing of Surgery and Residual Disease: a Post Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-301
Efficacy | ZEJULA (niraparib) for HCPs
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
Treatment Considerations With Niraparib
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
PARP Inhibitors. - ppt download
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
CME; Niraparib, Olaparib, bevacizumab, PRIMA trial, PAOLO-1
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial - Mirza - 2023 - Cancer - Wiley Online Library
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer | Targeted Oncology
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
